RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
+15.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.94B
AUM Growth
+$295M
(+8.1%)
Cap. Flow
+$40.9M
Cap. Flow
% of AUM
1.04%
Top 10 Holdings %
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$50.5M |
| 2 |
INZY
Inozyme Pharma
INZY
|
$23.1M |
| 3 |
Kymera Therapeutics
KYMR
|
$22.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$21.4M |
| 5 |
Humana
HUM
|
$21.3M |
Top Sells
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$41.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$31.6M |
| 3 |
Cigna
CI
|
$30.2M |
| 4 |
Amgen
AMGN
|
$29.7M |
| 5 |
Allogene Therapeutics
ALLO
|
$18.9M |
Sector Composition
| 1 | Healthcare | 90.05% |
| 2 | Consumer Staples | 1.43% |
| 3 | Consumer Discretionary | 0.93% |
| 4 | Industrials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
10x Genomics
TXG
$1.69B
| $9.48M | 0.24% |
76,000
| – | – |
|
|
RDUS
102
DELISTED
Radius Health, Inc.
RDUS
| $9.23M | 0.23% |
814,208
-189,051
| -19% | -$2.14M |
|
|
CHMA
103
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $9.22M | 0.23% |
2,144,225
+751,913
| +54% | +$3.23M |
|
|
PRTK
104
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $9.05M | 0.23% |
1,673,414
+18,250
| +1% | +$98.7K |
|
105
Nurix Therapeutics
NRIX
$697M
| $8.99M | 0.23% |
+257,514
| New | +$8.99M |
|
|
TBIO
106
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $8.75M | 0.22% |
642,646
-18,622
| -3% | -$253K |
|
|
GMDA
107
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $8.37M | 0.21% |
2,016,656
| – | – |
|
108
Jazz Pharmaceuticals
JAZZ
$7.77B
| $8.2M | 0.21% |
+57,500
| New | +$8.2M |
|
|
XENT
109
DELISTED
Intersect ENT, Inc
XENT
| $8.16M | 0.21% |
500,000
| – | – |
|
110
West Pharmaceutical
WST
$17.8B
| $7.84M | 0.2% |
28,500
-42,500
| -60% | -$11.7M |
|
111
Legend Biotech
LEGN
$6.46B
| $7.78M | 0.2% |
252,138
+46,242
| +22% | +$1.43M |
|
|
ZGNX
112
DELISTED
Zogenix, Inc.
ZGNX
| $7.46M | 0.19% |
415,982
| – | – |
|
113
Enliven Therapeutics
ELVN
$1.19B
| $7.3M | 0.19% |
89,736
-1,447
| -2% | -$118K |
|
|
MYOV
114
DELISTED
Myovant Sciences Ltd.
MYOV
| $7.2M | 0.18% |
512,711
+4,300
| +0.8% | +$60.4K |
|
115
Annexon
ANNX
$236M
| $7.16M | 0.18% |
+236,811
| New | +$7.16M |
|
116
Dynavax Technologies
DVAX
$1.17B
| $7.12M | 0.18% |
1,647,920
-12,200
| -0.7% | -$52.7K |
|
117
MacroGenics
MGNX
$123M
| $6.62M | 0.17% |
262,641
+28,125
| +12% | +$708K |
|
|
ODT
118
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $6.57M | 0.17% |
489,432
+52,201
| +12% | +$701K |
|
|
BCEL
119
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $6.3M | 0.16% |
+450,830
| New | +$6.3M |
|
|
NGM
120
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $5.74M | 0.15% |
360,454
+3,045
| +0.9% | +$48.4K |
|
121
Xenon Pharmaceuticals
XENE
$2.98B
| $5.71M | 0.14% |
515,711
| – | – |
|
|
ITOS
122
DELISTED
iTeos Therapeutics
ITOS
| $5.59M | 0.14% |
+226,681
| New | +$5.59M |
|
123
GoodRx Holdings
GDRX
$1.49B
| $5.56M | 0.14% |
+100,000
| New | +$5.56M |
|
124
Talphera
TLPH
$10.6M
| $5.36M | 0.14% |
+188,679
| New | +$5.36M |
|
125
Aclaris Therapeutics
ACRS
$224M
| $5.34M | 0.14% |
2,076,307
+432,292
| +26% | +$1.11M |
|